Cargando…
Epidemiologie von SARS-CoV-2-Infektion und COVID-19
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new β‑Coronavirus that was first detected in 2019 in Wuhan, China. In the ensuing months it has been transmitted worldwide. Here the authors present the current knowledge on the epidemiology of this virus. SARS-CoV‑2 replicates mainly...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Medizin
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7296906/ https://www.ncbi.nlm.nih.gov/pubmed/32548652 http://dx.doi.org/10.1007/s00108-020-00834-9 |
_version_ | 1783546921666740224 |
---|---|
author | Salzberger, B. Buder, F. Lampl, B. Ehrenstein, B. Hitzenbichler, F. Hanses, F. |
author_facet | Salzberger, B. Buder, F. Lampl, B. Ehrenstein, B. Hitzenbichler, F. Hanses, F. |
author_sort | Salzberger, B. |
collection | PubMed |
description | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new β‑Coronavirus that was first detected in 2019 in Wuhan, China. In the ensuing months it has been transmitted worldwide. Here the authors present the current knowledge on the epidemiology of this virus. SARS-CoV‑2 replicates mainly in the upper and lower respiratory tract and is primarily transmitted by droplets from asymptomatic and symptomatic infected subjects. The estimate for the basic reproduction number (R) is currently between 2 and 3, while the incubation period is 6 (median, range 2–14) days. Although most infections are uncomplicated, 5–10% of cases develop pneumonia, which can lead to hospitalization, respiratory failure and multiorgan failure. Risk factors for a complicated disease course include age, hypertension, chronic cardiovascular and pulmonary disease and immunodeficiency. The overall case fatality rate is 1.4%, with the rate rising in the sixth decade of life. Nosocomial and infections in medical personnel have been reported. Drastic reductions in social contact have been implemented in many countries with outbreaks of SARS-CoV‑2, leading to rapid reductions in R. Which of the measures have been effective is still unknown. |
format | Online Article Text |
id | pubmed-7296906 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Medizin |
record_format | MEDLINE/PubMed |
spelling | pubmed-72969062020-06-16 Epidemiologie von SARS-CoV-2-Infektion und COVID-19 Salzberger, B. Buder, F. Lampl, B. Ehrenstein, B. Hitzenbichler, F. Hanses, F. Internist (Berl) Schwerpunkt: COVID-19 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new β‑Coronavirus that was first detected in 2019 in Wuhan, China. In the ensuing months it has been transmitted worldwide. Here the authors present the current knowledge on the epidemiology of this virus. SARS-CoV‑2 replicates mainly in the upper and lower respiratory tract and is primarily transmitted by droplets from asymptomatic and symptomatic infected subjects. The estimate for the basic reproduction number (R) is currently between 2 and 3, while the incubation period is 6 (median, range 2–14) days. Although most infections are uncomplicated, 5–10% of cases develop pneumonia, which can lead to hospitalization, respiratory failure and multiorgan failure. Risk factors for a complicated disease course include age, hypertension, chronic cardiovascular and pulmonary disease and immunodeficiency. The overall case fatality rate is 1.4%, with the rate rising in the sixth decade of life. Nosocomial and infections in medical personnel have been reported. Drastic reductions in social contact have been implemented in many countries with outbreaks of SARS-CoV‑2, leading to rapid reductions in R. Which of the measures have been effective is still unknown. Springer Medizin 2020-06-16 2020 /pmc/articles/PMC7296906/ /pubmed/32548652 http://dx.doi.org/10.1007/s00108-020-00834-9 Text en © Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Schwerpunkt: COVID-19 Salzberger, B. Buder, F. Lampl, B. Ehrenstein, B. Hitzenbichler, F. Hanses, F. Epidemiologie von SARS-CoV-2-Infektion und COVID-19 |
title | Epidemiologie von SARS-CoV-2-Infektion und COVID-19 |
title_full | Epidemiologie von SARS-CoV-2-Infektion und COVID-19 |
title_fullStr | Epidemiologie von SARS-CoV-2-Infektion und COVID-19 |
title_full_unstemmed | Epidemiologie von SARS-CoV-2-Infektion und COVID-19 |
title_short | Epidemiologie von SARS-CoV-2-Infektion und COVID-19 |
title_sort | epidemiologie von sars-cov-2-infektion und covid-19 |
topic | Schwerpunkt: COVID-19 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7296906/ https://www.ncbi.nlm.nih.gov/pubmed/32548652 http://dx.doi.org/10.1007/s00108-020-00834-9 |
work_keys_str_mv | AT salzbergerb epidemiologievonsarscov2infektionundcovid19 AT buderf epidemiologievonsarscov2infektionundcovid19 AT lamplb epidemiologievonsarscov2infektionundcovid19 AT ehrensteinb epidemiologievonsarscov2infektionundcovid19 AT hitzenbichlerf epidemiologievonsarscov2infektionundcovid19 AT hansesf epidemiologievonsarscov2infektionundcovid19 |